ZA200803236B - Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders - Google Patents

Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders

Info

Publication number
ZA200803236B
ZA200803236B ZA200803236A ZA200803236A ZA200803236B ZA 200803236 B ZA200803236 B ZA 200803236B ZA 200803236 A ZA200803236 A ZA 200803236A ZA 200803236 A ZA200803236 A ZA 200803236A ZA 200803236 B ZA200803236 B ZA 200803236B
Authority
ZA
South Africa
Prior art keywords
adenosine
extra
treatment
receptor antagonists
movement disorders
Prior art date
Application number
ZA200803236A
Other languages
English (en)
Inventor
Grzelak Michael
Pond Annamarie
Hunter John
Varty Geoffrey
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200803236B publication Critical patent/ZA200803236B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200803236A 2005-10-13 2008-04-11 Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders ZA200803236B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/249,796 US20060128694A1 (en) 2002-12-19 2005-10-13 Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Publications (1)

Publication Number Publication Date
ZA200803236B true ZA200803236B (en) 2009-03-25

Family

ID=37719335

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803236A ZA200803236B (en) 2005-10-13 2008-04-11 Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders

Country Status (11)

Country Link
US (1) US20060128694A1 (ja)
EP (1) EP2001511A1 (ja)
JP (1) JP2009511588A (ja)
CN (1) CN101325974A (ja)
AU (1) AU2006304102A1 (ja)
BR (1) BRPI0617415A2 (ja)
CA (1) CA2625859A1 (ja)
NO (1) NO20082175L (ja)
TW (1) TW200800263A (ja)
WO (1) WO2007047293A1 (ja)
ZA (1) ZA200803236B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1631294B1 (en) * 2003-06-10 2010-09-15 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2116967C (en) * 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
ES2686123T3 (es) * 2002-01-28 2018-10-16 Kyowa Hakko Kogyo Co., Ltd Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
JP4527712B2 (ja) * 2003-04-23 2010-08-18 シェーリング コーポレイション ２−アルキニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニストおよび２−アルケニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト
ES2342082T3 (es) * 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
CA2571242A1 (en) * 2004-06-17 2006-01-26 The Regents Of The University Of California Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
CN101119998A (zh) * 2004-12-21 2008-02-06 先灵公司 吡唑并[1,5－A]嘧啶腺苷A2a受体拮抗剂

Also Published As

Publication number Publication date
JP2009511588A (ja) 2009-03-19
EP2001511A1 (en) 2008-12-17
US20060128694A1 (en) 2006-06-15
CA2625859A1 (en) 2007-04-26
NO20082175L (no) 2008-07-11
AU2006304102A1 (en) 2007-04-26
BRPI0617415A2 (pt) 2011-07-26
TW200800263A (en) 2008-01-01
WO2007047293A1 (en) 2007-04-26
CN101325974A (zh) 2008-12-17

Similar Documents

Publication Publication Date Title
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
ZA200802552B (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
EP1723227A4 (en) NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
EP1877068A4 (en) NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
IL192426A0 (en) Prokineticin 2 receptor antagonists
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL179462A0 (en) Use of the receptor gpr86
IL192424A0 (en) Prokineticin 1 receptor antagonists
ZA200709147B (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
EP1948675A4 (en) METHOD AND COMPOSITIONS FOR TREATING MARFAN SYNDROME AND RELATED DISEASES
PL1951658T3 (pl) Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
PT1922309E (pt) Derivados de n-fenil-2-pirimidina-amina e processo para a sua preparação
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
IL187972A0 (en) Piperazine-pipridine antagonists and agonists of the 5-ht1a receptor
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
PL1751175T3 (pl) Antagoniści receptora IL-1, kompozycje i sposoby leczenia
HK1110025A1 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility
IL238702A0 (en) History of tetrazole-modified arylamides and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
HK1102298A1 (en) Backrest supporting posture of infants and supporting device for the infants using the said backrest
HK1121378A1 (en) Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
EP1937242A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES AND ADDITIVES